FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an...

Area of Science:

• Nephrology
• Immunology
• Transplantation Medicine

Background:

• De novo renal transplant recipients at high risk of delayed graft function (DGF) require effective immunosuppression.
• FTY720 (fingolimod) and everolimus are used in immunosuppressive regimens.
• Optimizing immunosuppression to prevent rejection and preserve graft function is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of FTY720 in combination with everolimus and steroids in de novo renal transplant recipients.
• To assess the impact of this regimen on delayed graft function (DGF), acute rejection, graft loss, and renal function.

Main Methods:

• An exploratory, multicenter, open-label study involving 56 patients.
• Patients received FTY720 and everolimus pre- and post-transplantation for 12 months.
• No induction therapy was administered; recruitment was terminated early.

Main Results:

• The primary endpoint showed a 15.4% rate of graft loss or death at three months.
• Biopsy-confirmed acute rejection occurred in 42.3% of patients.
• Death or graft loss at 12 months was 36.0% in the DGF group and 25.9% in the non-DGF group.
• Estimated creatinine clearance at 12 months was 56 mL/min in both groups.

Conclusions:

• FTY720-based immunosuppressive regimens did not demonstrate apparent benefits for preventing acute rejection or preserving renal function in high-risk renal transplant recipients.
• The observed rates of rejection and graft loss suggest this regimen may not be advantageous for this patient population.
• Further research with comparator arms would be needed to definitively assess FTY720's role.